Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.
BRAFV600
KRASG12C
cetuximab
colorectal cancer
personalized treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
received:
12
12
2023
revised:
10
01
2024
accepted:
16
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC. Cetuximab has emerged as a pivotal partner for novel therapies in specific molecular subgroups, including
Identifiants
pubmed: 38254903
pii: cancers16020412
doi: 10.3390/cancers16020412
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng